GW Pharmaceuticals has announced its Sativex spray has failed a Phase III pain relief trial among multiple sclerosis patients.
The company added that Sativex had a very high patient response rate, but that the results narrowly failed to reach statistical significance because of an unexpectedly large response to a placebo treatment among the test group.
"The previous trial yielded a highly significant reduction in pain and it is extremely disappointing that this couldn't be replicated," said Paul Cuddon, an analyst at KBC Peel Hunt. "The company attribute this to a large response in the placebo group. While valid, this indicates that the effect of Sativex is marginal, and we retain our doubts as to whether the product will ever prove a commercial success in any of the indications.
More
No comments:
Post a Comment